CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
CURRENT ASSETS
Cash and cash equivalents
Prepaid expenses	147,708
Total current assets	147,708
TOTAL ASSETS	147,708
Current Liabilities
Accounts payable and accrued liabilities	407,654	328,178
Accounts payable to related party	585,897	454,665
Related party advances	7,979	6,295
Advances payable	62,150	59,650
Note payable	300,000	300,000
Current portion of convertible notes payable, net of discount of $0, respectively	28,408	59,710
Accrued interest payable	224,269	225,363
Total current liabilities	1,616,357	1,433,861
TOTAL LIABILITIES	1,616,357	1,433,861
STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value; 1,162,921,101 and 996,119,530 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively	1,162,921	996,119
Preferred stock, value
Series A Preferred Stock, $0.001 par value; 0 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively
Series D Preferred Stock, $0.001 par value; 0 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively
Series E Preferred Stock, $0.001 par value; 1,000,000 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively	1,000	1,000
Series F Preferred Stock; $0.001 par value; 128,991 shares issued and outstanding at March 31, 2024 and September 30, 2023	129	129
Additional paid-in capital	18,013,388	18,022,916
Stock payable, consisting of 100,000,000 shares to be issued at March 31, 2024 and September 30, 2023, respectively	179,000
Accumulated deficit	(20,825,087)	(20,454,025)
TOTAL STOCKHOLDERS' DEFICIT	(1,468,649)	(1,433,861)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, value	0	0
Series D Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, value	0	0
TOTAL STOCKHOLDERS' DEFICIT
Series E Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, value	1,000	1,000
TOTAL STOCKHOLDERS' DEFICIT	1,000	1,000
Series F Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, value	129	129
TOTAL STOCKHOLDERS' DEFICIT	$ 129	$ 129

GlobeStar Therapeutics Corp 10-Q